Related Experiment Video
Updated: Mar 10, 2026

Inducement and Evaluation of a Murine Model of Experimental Myopia
Published on: January 22, 2019
Efficacy and Rebound Effects of Repeated Low-Level Red Light versus High-Concentration Atropine for Myopia Control in
Jiamin Xie1,2,3,4,5, Zhihua Zhang1,2,3,4,5, Ting Zhang6
1Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Background:
To compare the efficacy of repeated low-level red light (RLRL) and high-concentration atropine (HCA, 1%) in myopia control and evaluate rebound effects after cessation.
Methods:
In this 15-month, prospective, single-blinded randomized controlled trial, 136 myopic children (6-12 years) were randomly assigned to RLRL or HCA (1:1). Treatment lasted 12 months followed by a 3-month washout. Outcomes included change in axial length (AL), spherical equivalent refraction (SER), subfoveal choroidal thickness (SFChT), and safety.
Results:
A total of 116 children completed ≥ 1 follow-up (RLRL: 65, HCA: 51). At 12 months, RLRL showed superior efficacy: AL regressed by -0.014 mm (95% CI: -0.067 to 0.039) versus a 0.094 mm increase with HCA (95% CI: 0.046-0.141; p = 0.005). SER decreased by 0.24 D (95% CI: 0.093-0.387) in RLRL and increased by 0.035 D (95% CI: -0.154 to 0.083) in HCA (p = 0.008), while SFChT increased by 26.000 μm (95% CI: 18.082-33.918) and 12.761 μm (95% CI: 3.867-21.655; p = 0.032), respectively. During the 3-month washout, AL elongation was slightly greater in RLRL (0.163 mm) compared to HCA (0.115 mm; p = 0.014). Higher compliance (≥ 75%) with RLRL correlated with better 12-month efficacy (AL: -0.064 mm vs. 0.084 mm; p = 0.011) but worse rebound (AL: 0.183 mm vs. 0.122 mm; p = 0.02). No severe adverse events were reported.
Conclusions:
RLRL exhibited superior 12-month efficacy over HCA (1%) but was associated with slightly higher rebound. Optimizing RLRL regimens, including implementing reduced dosing and tapered withdrawal, could sustain benefits while limiting rebound.
Trial Registration:
Chinese Clinical Trial Registry: ChiCTR2100051940.
More Related Videos
05:56Scleral Cross-linking Using Riboflavin and Ultraviolet-A Radiation for Prevention of Axial Myopia in a Rabbit Model
Published on: April 3, 2016
06:19Comparison of Three Clinical Stereoscopic Methods for Measuring Binocular Visual Function During Amblyopic Treatment in Unilateral Amblyopia
Published on: September 27, 2024
Related Concept Videos
Ophthalmic Drug Delivery Systems
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...